Newsletter

Welcome to

PROVIDING PATIENTS THERAPEUTIC RELIEF FROM SERIOUS DISEASES WITH HIGH UNMET MEDICAL NEED

Relief is a biopharmaceutical company focused on serious illnesses with high unmet medical need. Through rapid development of late-stage clinical assets, we aim to bring therapeutic options to patients as quickly as possible.

Latest News

  • COVID-19 PROJECT

    COVID-19 PROJECT

    Realizing the urgent unmet medical need created by the 2019 SARS-CoV-2 pandemic, Relief mounted a swift plan of action to respond to one of the largest healthcare disasters of our time by rapidly advancing our proprietary asset RLF-100™ into clinical development and towards approval in COVID-19 induced lung injury. Within a year the results of a Phase 2b/3 trial with IV RLF-100 performed by NeuroRX, a company partner of Relief, have become available, demonstrating, according to NeuroRX, encouraging outcomes. Several additional clinical studies with RLF-100 in IV or inhaled formulation have been initiated.